{"id":53377,"date":"2026-01-08T20:49:13","date_gmt":"2026-01-08T12:49:13","guid":{"rendered":"https:\/\/flcube.com\/?p=53377"},"modified":"2026-01-08T20:49:14","modified_gmt":"2026-01-08T12:49:14","slug":"viva-biotech-and-cms-forge-ai-powered-drug-development-alliance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53377","title":{"rendered":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance"},"content":{"rendered":"\n<p><strong>Viva Biotech<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1873:HKG\">HKG: 1873<\/a>) and <strong>China Medical System Holdings Limited<\/strong> (CMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/8A8:SGX\">SGX: 8A8<\/a>) announced a <strong>collaborative development agreement<\/strong> to jointly research and develop a <strong>novel targeted oral small\u2011molecule inhibitor<\/strong>. The partnership leverages Viva\u2019s <strong>AI\u2011powered end\u2011to\u2011end drug R&amp;D system<\/strong> and CMS\u2019s <strong>clinical development, regulatory, and commercialization expertise<\/strong> to accelerate the program from discovery to market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Viva Biotech (1873.HK), China Medical System Holdings (0867.HK)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Joint development agreement<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Novel targeted oral small\u2011molecule inhibitor (undisclosed target)<\/td><\/tr><tr><td><strong>Technology Focus<\/strong><\/td><td>AI\u2011powered drug discovery (Viva), clinical development &amp; commercialization (CMS)<\/td><\/tr><tr><td><strong>Development Goal<\/strong><\/td><td>Advance to Pre\u2011clinical Candidate (PCC) stage and through clinical trials<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>&#8220;Strong\u2011strong&#8221; alliance integrating discovery through commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>Viva Biotech\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Driven Discovery<\/strong>: Utilizes <strong>mature AI\u2011powered end\u2011to\u2011end drug R&amp;D system<\/strong><\/li>\n\n\n\n<li><strong>FIC Expertise<\/strong>: Extensive experience in <strong>First\u2011in\u2011Class (FIC) drug discovery<\/strong><\/li>\n\n\n\n<li><strong>PCC Focus<\/strong>: Drives project efficiently toward <strong>Pre\u2011clinical Candidate (PCC)<\/strong> nomination<\/li>\n<\/ul>\n\n\n\n<p><strong>CMS\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development<\/strong>: Deep expertise in <strong>trial design, execution, and regulatory registration<\/strong><\/li>\n\n\n\n<li><strong>Commercialization<\/strong>: Proven track record in <strong>market access, pricing, and launch<\/strong><\/li>\n\n\n\n<li><strong>Integration<\/strong>: Provides <strong>seamless transition<\/strong> from pre\u2011clinical to market entry<\/li>\n<\/ul>\n\n\n\n<p><strong>Synergy<\/strong>: Combines <strong>AI\u2011driven speed<\/strong> with <strong>established clinical\/commercial infrastructure<\/strong>, reducing development risk and timeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-platform\">Technology &amp; Platform<\/h2>\n\n\n\n<p><strong>Viva\u2019s AI System<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Identification<\/strong>: Machine learning models predict druggable targets<\/li>\n\n\n\n<li><strong>Molecule Generation<\/strong>: AI de novo design of small molecules with optimized properties<\/li>\n\n\n\n<li><strong>ADMET Prediction<\/strong>: In silico screening for absorption, distribution, metabolism, excretion, and toxicity<\/li>\n\n\n\n<li><strong>Cycle Time<\/strong>: Reduces <strong>discovery timeline by 30\u201140%<\/strong> vs. traditional methods<\/li>\n<\/ul>\n\n\n\n<p><strong>CMS\u2019s Development Engine<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway<\/strong>: Established relationships with <strong>CDE\/NMPA<\/strong> for expedited review<\/li>\n\n\n\n<li><strong>Clinical Operations<\/strong>: <strong>3,000+ investigator sites<\/strong> across China<\/li>\n\n\n\n<li><strong>Commercial Network<\/strong>: <strong>10,000+ hospital relationships<\/strong> and <strong>national sales force<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Target Indication<\/strong>: Undisclosed, but analysis suggests <strong>oncology or immunology<\/strong> given the targeted small\u2011molecule inhibitor focus.<\/p>\n\n\n\n<p><strong>China Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Small\u2011Molecule Market<\/strong>: <strong>\u00a5120\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>AI\u2011Discovered Drugs<\/strong>: <strong>&lt;5%<\/strong> of pipeline, but growing rapidly with <strong>policy support<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Financial Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Sales<\/strong>: <strong>\u00a52\u20113\u202fbillion<\/strong> (US$280\u2011420\u202fmillion) projected for a successful FIC small molecule by 2030<\/li>\n\n\n\n<li><strong>Development Cost<\/strong>: <strong>\u00a5400\u2011600\u202fmillion<\/strong> (US$56\u201184\u202fmillion) from PCC to NDA; <strong>AI reduces cost by 20\u201125%<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<p><strong>Structure<\/strong>: Joint development with <strong>shared costs and profits<\/strong>; specific terms undisclosed.<\/p>\n\n\n\n<p><strong>Typical Model<\/strong> (industry benchmark):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Viva<\/strong>: Funds discovery through PCC (<strong>\u00a580\u2011120\u202fmillion<\/strong>)<\/li>\n\n\n\n<li><strong>CMS<\/strong>: Funds clinical development (<strong>\u00a5300\u2011500\u202fmillion<\/strong>)<\/li>\n\n\n\n<li><strong>Profit Split<\/strong>: <strong>50\/50<\/strong> on net sales post\u2011launch<\/li>\n<\/ul>\n\n\n\n<p><strong>Milestone Framework<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PCC Nomination<\/strong>: \u00a520\u202fmillion milestone<\/li>\n\n\n\n<li><strong>IND Approval<\/strong>: \u00a550\u202fmillion milestone<\/li>\n\n\n\n<li><strong>Phase\u202fIII Initiation<\/strong>: \u00a5100\u202fmillion milestone<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership\u2019s development timeline, cost savings, and commercial potential. Actual results may differ materially due to AI model accuracy, clinical trial outcomes, regulatory changes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[325,19,844,1353,4256,1352],"class_list":["post-53377","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-medical-system","tag-cro-cmo-cdmo","tag-hkg-0867","tag-hkg-1873","tag-sgx-8a8","tag-viva-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Viva Biotech and CMS Forge AI-Powered Drug Development Alliance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&amp;D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53377\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance\" \/>\n<meta property=\"og:description\" content=\"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&amp;D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53377\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T12:49:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T12:49:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance\",\"datePublished\":\"2026-01-08T12:49:13+00:00\",\"dateModified\":\"2026-01-08T12:49:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 0867\",\"HKG: 1873\",\"SGX: 8A8\",\"VIVA Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53377#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53377\",\"name\":\"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-08T12:49:13+00:00\",\"dateModified\":\"2026-01-08T12:49:14+00:00\",\"description\":\"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53377\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53377#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance - Insight, China&#039;s Pharmaceutical Industry","description":"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53377","og_locale":"en_US","og_type":"article","og_title":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance","og_description":"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.","og_url":"https:\/\/flcube.com\/?p=53377","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T12:49:13+00:00","article_modified_time":"2026-01-08T12:49:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53377#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53377"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance","datePublished":"2026-01-08T12:49:13+00:00","dateModified":"2026-01-08T12:49:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53377"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","CRO \/ CMO \/ CDMO","HKG: 0867","HKG: 1873","SGX: 8A8","VIVA Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53377#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53377","url":"https:\/\/flcube.com\/?p=53377","name":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-08T12:49:13+00:00","dateModified":"2026-01-08T12:49:14+00:00","description":"Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8) announced a collaborative development agreement to jointly research and develop a novel targeted oral small\u2011molecule inhibitor. The partnership leverages Viva\u2019s AI\u2011powered end\u2011to\u2011end drug R&D system and CMS\u2019s clinical development, regulatory, and commercialization expertise to accelerate the program from discovery to market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53377#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53377"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53377#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viva Biotech and CMS Forge AI-Powered Drug Development Alliance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53377"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53377\/revisions"}],"predecessor-version":[{"id":53380,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53377\/revisions\/53380"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}